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Pancreatic cancer is one of the major causes of cancer-related
deaths in industrialized countries (Poston et al, 1991; Warshaw
and Castillo, 1992; Bramhall et al, 1995). Most pancreatic cancer
patients were first diagnosed at an advanced stage of the disease
and only 3% of all these patients survived for 5 years (Niederhuber
et al, 1995). In addition to difficulties in an early diagnosis and
lack of effective treatment, the aggressive behaviour of pancreatic
cancer cells, i.e. potent invasive activity to the surrounding tissues
and early metastatic ability to the distant organs, lead to a poor
clinical outcome. Thus, a better understanding of mechanisms by
which pancreatic cancers exhibit highly invasive and metastatic
potential is needed for development of therapeutic intervention. 
The invasive and metastatic ability of cancer depends on
changes in adhesive properties of the cells, degradation of the
extracellular matrix, and a concomitant induction of cell move-
ment. Stromal cells in cancer tissues influence the growth, inva-
sion and metastasis of cancer cells. Growth, migration, and
invasion of cancer cells were markedly accelerated by a broad
spectrum of fibroblasts in vivo (Camps et al, 1990) and in vitro
(Grey et al, 1989). Over 90% of pancreatic cancers originate from
pancreatic duct epithelial cells, accompanied by abundant stromal
components. Therefore, local and mutual interactions between
cancer cells and stromal cells are likely to be particularly impor-
tant in regulating malignant behaviour in the pancreas. 
Hepatocyte growth factor (HGF), initially identified and cloned
as a potent mitogen for hepatocytes (Nakamura et al, 1984, 1989;
Miyazawa et al, 1989), is a stromal-derived multi-potent factor
that exhibits mitogenic, motogenic, and morphogenic activities.
Accumulating evidence has shown that HGF plays a distinct role
in tumour–stromal interactions (Seslar et al, 1993; Rosen et al,
1994; Matsumoto et al, 1996; Inoue et al, 1997; Nakamura et al,
1997; Jiang et al, 1999). HGF has potent motogenic activity on
various types of carcinoma cells, leading to the dissociation,
scattering and migration of cells (Weidner et al, 1990; Jiang et al,
1993, 1999; Matsumoto et al, 1994, 1996; Jeffers et al, 1996;
Rosen et al, 1996; Inoue et al, 1997; Nakamura et al, 1997). 
The c-Met/HGF receptor of membrane-spanning tyrosine
kinase is expressed in a wide variety of carcinoma cells, including
pancreatic cancer cells (Ebert et al, 1994; Di Renzo et al, 1995;
Furukawa et al, 1995; Vila et al, 1995; Jiang et al, 1999). The inva-
sion of pancreatic cancer cells was found to be accelerated with
the addition of HGF with activation of the u-PA/u-PA receptor
proteolytic system in vitro (Paciucci et al, 1998). Thus, functional
coupling between HGF and the c-Met/HGF receptor in pancreatic
cancer cells may play a key role in the invasion and metastasis of
pancreatic cancer. 
Based on the involvement of HGF on tumour malignancy, we
earlier prepared an antagonist for HGF (Date et al, 1997). This
HGF-antagonist, termed NK4, is composed of the N-terminal
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hairpin domain and subsequent four kringle domains of the a-
subunit of HGF. NK4 binds to the c-Met/HGF receptor, but does
not induce tyrosine phosphorylation of c-Met (Date et al, 1997).
While competitive inhibitory effects of NK4 on HGF and c-
Met/receptor interaction have been demonstrated in some distinct
types of human cancer cells (Date et al, 1998; Hiscox et al, 2000;
Kuba et al, 2000; Parr et al, 2000), inhibitory and promising thera-
peutic effects of NK4 have to be evaluated in cases of highly
aggressive pancreatic cancer. In the current study, cancer–stromal
interaction through HGF and c-Met coupling and inhibitory effects
of NK4 were investigated in human pancreatic cancer cells. The
invasion of pancreatic cancer cells was potently stimulated by
HGF, cocultivation with fibroblasts, and by ascitic fluid from
patients who had undergone pancreatic cancer resection, but this
invasion was almost completely inhibited by NK4. The potential
inhibition of pancreatic cancer invasion and dissemination by NK4
was thus deemed worthy of investigation. 
MATERIALS AND METHODS 
Materials 
Human recombinant HGF was purified from the conditioned
medium of Chinese hamster ovary cells transfected with human
HGF cDNA (Nakamura et al, 1989; Seki et al, 1990). Polyclonal
antibody against human HGF was prepared from the serum of a
rabbit immunized with human recombinant HGF and IgG was
purified using protein A-Sepharose (Pharmacia Biotech, Uppsala).
Anti-human HGF IgG (1 mgm l –1) completely neutralized the
biological activities of 1 ng ml–1 human HGF. NK4 was prepared
by proteolytic digestion with elastase, as described elsewhere
(Date et al, 1997). Anti-c-Met polyclonal antibody (C-12) was
obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA).
Human recombinant basic fibroblast growth factor (bFGF) and
transforming growth factor-a (TGF-a) were obtained from R&D
Systems (Minneapolis, MN). 
Cell culture 
Eight human pancreatic cancer cell lines were used in this study:
BxPC-3 and MIA PaCa-2 were provided by Japanese Cancer
Resource Bank (Tokyo, Japan); AsPC-1, H-48N, KP-1N, KP-2,
KP-3 and SUIT-2 were generously donated by Dr H Iguchi
(National Kyushu Cancer Center, Fukuoka, Japan). Fibroblasts
were initially proliferated outward from pancreatic tissue obtained
at surgery, and used during 10–15 passages. 
AsPC-1, H-48N, KP-1N, KP-2, KP-3 and SUIT-2 were cultured
in RPMI supplemented with streptomycin, penicillin and 10%
fetal bovine serum (FBS) at 37˚C in a humidified atmosphere
containing 5% CO2. BxPC-3, MIA PaCa-2 and fibroblasts were
cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with streptomycin, penicillin and 10% FBS. 
Assay for cell growth and scattering 
For measurement of cell proliferation, human pancreatic cancer
cells in RPMI or DMEM with 10% FBS were respectively plated
at 2.5 ´ 103 cells cm–2 onto 24-well tissue culture plates and
cultured for 24 h. The culture media were replaced by fresh RPMI
or DMEM containing 5% FBS and the cells were cultured in
absence or presence of 10 ng ml–1 (110 pM) HGF for 72 h. The
cells were also cultured with the addition of HGF in the absence or
presence of 110 nM NK4. The number of cells was counted using
a cell counter (Coulter, Bedfordshire) after dissociation with
trypsin-EDTA (0.05% trypsin and 0.02% EDTA in PBS). For the
cell-scattering assay, pancreatic cancer cells were plated at 250
cells cm–2 in RPMI or DMEM containing 10% FBS onto six-well
plates and cultured for 4–7 days. After the media were changed,
110 pM HGF, with or without 110 nM NK4, was added and 
after incubation for 24 h scattering of cells was microscopically
observed. 
Migration assay 
Migration of tumour cells was evaluated using a Transwell
chamber (Corning Coster Co, Cambridge, MA) equipped with a
filter membrane with 8-mm pores. Cancer cells were plated at 5 ´
104 cells cm–2 or 1 ´ 104 cells cm–2 in RPMI or DMEM containing
10% FBS onto the upper compartment of the chamber. Cells were
cultured in the absence or presence of HGF for 24 h, fixed in 70%
ethanol and stained with haematoxylin and eosin. Cells migrating
to the undersurface of the membrane through the pores, as seen
microscopically, were counted. Five microscopic fields (´ 200)
were randomly selected for cell counting. To examine the
inhibitory effects on migration of tumour cells, NK4 and antibody
against HGF were added to the lower compartment. The migration
assays were independently performed three times and similar
results were obtained in each experiment. 
Invasion assay 
Invasion of tumour cells was measured using a 24-well Matrigel
invasion chamber (Becton Dickinson, Bedford, MA). The pancre-
atic cancer cells suspended in RPMI or DMEM containing 2%
FBS were added to the inner cup of a Matrigel invasion chamber at
a density of 1 ´ 105 cells cm–2. HGF or ascitic fluid, and/or NK4
were added to the medium of the outer cup. After 24 h cultivation,
cells that degraded the Matrigel and migrated through 8-mm pores
of the membrane to the opposite side of the membrane were
counted after they had been stained with haematoxylin and eosin. 
For cocultivation of pancreatic cancer cells and fibroblasts,
human fibroblasts were initially seeded on the outer cup of a
Matrigel invasion chamber at a density of 1.5 ´ 104 cells cm–2 and
cultured in DMEM containing 10% FBS for 24 h. The medium
was replaced by fresh medium supplemented with 2% FBS, and
pancreatic cancer cells were seeded on the inner cup of the inva-
sion chamber at a density of 1 ´ 105 cells cm–2 and cultured for 
24 h. After cocultivation, cells which passed through the
membrane were counted. The invasion assays were independently
performed three times and similar results were obtained in each
experiment. 
Western immunoblotting of the c-Met/HGF receptor 
After reaching confluency, carcinoma cells were scraped,
collected by centrifugation, and solubilized in 500 ml of ice-cold
lysis buffer composed of 150 mM NaCl, 20 mM Tris-HCl (pH
7.5), 10 mM EDTA, 5 mgm l –1 leupeptin, 1 mM phenylmethy
sulfonyl fluoride and 0.5% (v/v) Triton X-100. The supernatants
were collected by centrifugation and cell lysates were subjected to866 N Maehara
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SDS-PAGE at 100 mg protein lane–1, under reducing conditions,
using a 6% polyacrylamide gel. The proteins were transferred to a
polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA),
and the membrane was incubated with anti-human Met antibody,
biotinylated goat anti-rabbit IgG (Vector, Burlingame, CA), and
the peroxidase-conjugated avidin–biotin complex. The c-Met/
HGF receptor was visualized using an ECL enhanced chemilumi-
nescence method (Amersham, Little Chalfont). 
Collection of ascitic fluid and measurement of HGF 
Ascitic fluid was obtained from peritoneal drain tubes from three
Japanese patients with pancreatic cancer who had undergone
resection for primary pancreatic cancer in the Department of
Surgery and Oncology, Graduate School of Medical Sciences,
Kyushu University. The present study was carried out with the
approval of the ethical committee organized by the senior staff in
the Department of Surgery and Oncology. Written informed
consent for collecting ascitic fluid samples for research was
obtained from each patient prior to the surgery. The supernatants
of the samples, collected by centrifugation at 2200 rpm for 20 min,
were stored at –80˚C until assay. 
HGF concentration in the conditioned media and the ascitic
fluid was measured using an enzyme-linked immunosorbent assay
(ELISA) kit (Institute of Immunology, Tokyo), according to the
manufacturer’s instructions. The lower detection limit of this assay
is 0.10 ng ml–1. 
RESULTS 
Expression of c-Met/HGF receptor 
We first analysed expression of the c-Met/HGF receptor in
human pancreatic carcinoma cells by Western immunoblotting.
The b subunit (Mr 145 000, p 145 b) of c-Met/HGF receptor was
identified in all carcinoma cell lines and the precursor form of 
c-Met/HGF receptor (Mr 170 000, Pr 170) was identified in seven
cell lines but not PaCa-2 (Figure 1). These pancreatic cancer cells
expressed varying levels of c-Met/HGF receptor: relatively
strong expression was seen in AsPC-1 and SUIT-2 cells, and
medium or low expression was seen in BxPC-3, H-48N, KP-1N,
KP-2 and KP-3 cells. MIA PaCa-2, which did not show any
response to HGF (see below) had the weakest expression of the b
subunit and no expression of the precursor of the c-Met/HGF
receptor. Thus, eight distinct types of human pancreatic cancer
cell lines expressed varying levels of c-Met/HGF receptor, 
which means that these cancer cells are potential target cells of
HGF. 
NK4 inhibits HGF-induced cell growth and scattering 
We next analysed effects of HGF on proliferation of pancreatic
cancer cells (Table 1). With the addition of 10 ng ml–1 (110 pM)
HGF, proliferation of KP-3 and SUIT-2 pancreatic cancer cells
were stimulated by 1.4-fold (Table 1). However, cell proliferation
was not affected in other lines. On the other hand, stimulatory
effects of 110 pM HGF on proliferation of the KP-3 and SUIT-2
cells was almost completely inhibited in the presence of 110 nM
NK4 (not shown). 
As HGF is a potent stimulator of epithelial cell colony dissocia-
tion, which results in scattering of cells (Gherardi et al, 1989;
Weidner et al, 1990), we tested the effects of HGF on scattering of
pancreatic cancer cells in monolayer culture (Figure 2A). Six
pancreatic cancer cells (BxPC-3, H-48N, KP-1N, KP-2, KP-3 and
SUIT-2) formed colonies, displaying varying levels of intercellular
adhesions. The addition of 10 ng ml–1 HGF led to dissociation of
the colonies and stimulated motility, resulting in scatterings of KP-
2, KP-3 and SUIT-2 cells. Although HGF did not cause a remark-
able dissociation of colonies in H-48N and KP-1N lines, these
cells had a flattened and spindle-like appearance when HGF was
added, and several cells were scattered, thereby suggesting that
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Figure 1 Expression of c-Met/HGF receptor in human pancreatic cancer
cell lines. The cells were solubilized in lysis buffer and the proteins were
electrophoresed on SDS-PAGE, under reducing conditions. The proteins
were transferred onto the membrane and probed with antibodies against the
c-Met/HGF receptor 
Table 1 c-Met/HGF receptor expression, HGF production and biological effects of HGF on pancreatic cancer cells 
Pancreatic cancer  c-Met/HGF receptor HGF production Biological effects 
cell lines expression
Growtha Migrationb Invasionb
AsPC-1 +++ undetectable no effect +++ +++ 
BxPC-3 + 0.1 ng ml–1 no effect no effect no effect 
H-48N ++ 0.1 ng ml–1 no effect +++ ++ 
KP-1N + 0.2 ng ml–1 no effect +++ ++ 
KP-2 ++ 0.1 ng ml–1 no effect +++ +++ 
KP-3 ++ 0.1 ng ml–1 1.4 +++ +++ 
PaCa-2 + undetectable no effect no effect no effect 
SUIT-2 +++ undetectable 1.4 +++ +++ 
aStimulation in fold increase; b++ = stimulation in 2–3-fold increase; +++ = > 3-fold increase Inhibition of pancreatic cancer invasion by NK4 867
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HGF weakly stimulated the motility of these cells. Cell scattering
was not induced by HGF in BxPC-3 cells. AsPC-1 and MIA PaCa-
2 cells seemed to form loose cell–cell interactions, showing rela-
tively scattered appearances even without HGF and no remarkable
change was observed even after the addition of HGF. To determine
if NK4 would inhibit HGF-induced scattering of pancreatic cancer
cells, effects of NK4 on KP-2, KP-3 and SUIT-2 cells were 
examined. As shown in Figure 2B, cell scattering of SUIT-2 
cells induced by 110 pM HGF was completely blocked by 
110 nM NK4, whereas NK4 alone had no effect on the cell
scattering. Similar inhibitory effects of NK4 on HGF-induced cell
scattering were seen in KP-2 and KP-3 lines (not shown). 
NK4 inhibits migration and invasion of pancreatic
cancer cells 
We measured the migration of carcinoma cells in vitro using a
Transwell chamber. In the absence of HGF, the number of cells
migrating through pores to the opposite side of the membrane was
20 field–1 or fewer. In the presence of 10 ng ml–1 HGF, migration of
the cells was evidently stimulated in AsPC-1, H-48N, KP-1N, KP-
2, KP-3 and SUIT-2 lines by 3.4-fold, 5.5-fold, 5.1-fold, 10.5-fold,
6.3-fold and 13.7-fold, respectively, compared to cultures without
HGF (Figure 3A). Although HGF stimulated migration of these
cells, a small number of cells migrated even in the presence of
HGF in AsPC-1, BxPC-3, and H-48N cells. When migration of
these cells was examined in the presence of other growth factors,
bFGF and TGF-a but not TGF-b and platelet-derived growth
factor weakly stimulated migration of AsPC-1 cells, whereas these
growth factors had no obvious effect on migration of BxPC-3 and
H-48N cells (not shown). Therefore, these cells seem to have a
general poor motility, compared to other cells. On the other hand,
migration of the cells was not significantly stimulated in BxPC-3
and MIA PaCa-2 by HGF. We then examined effects of NK4 on
HGF-induced migration of SUIT-2 cells, which showed an evident
responsiveness to HGF. NK4 inhibited the stimulatory effects of
HGF on migration of SUIT-2 cells, in a dose-dependent manner
(Figure 3B): a significant inhibition of migration was seen at 0.33
nM NK4, a 10-fold higher concentration than that of HGF (33 pM)
and 33 nM of NK4 prohibited the HGF-induced migration of
None
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HGF 110pM +
NK4 110 nM NK4 110 nM
AsPC-1
H-48N
KP-2
PaCa-2
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SUIT-2
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Figure 2 (A) Enhancement of cell scattering of human pancreatic cancer cells by HGF, (B) inhibition of HGF-induced cell scattering by NK4 in SUIT-2 cells.
Pancreatic cancer cells were cultured for 24 h in the presence of 10 ng ml–1 (110 pM) HGF and/or 110 nM NK4.868 N Maehara
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SUIT-2 cells. However, 330 nM NK4 alone had no effect on
migration of SUIT-2 cells. On the other hand, bFGF and TGF-a
also stimulated migration of the cells, whereas NK4 did not inhibit
migration of the cells stimulated by bFGF and TGF-a (Figure 3B).
Similarly, 110 pM HGF stimulated migration of KP-1N and KP-3
cells, but the migration of these cells enhanced by HGF was almost
completely inhibited by 110 nM NK4 (Figure 3C). 
To determine if HGF would affect invasion of pancreatic carci-
noma cells, cells were cultured in a Matrigel invasion chamber in
the absence or presence of HGF. Except for BxPC-3 and MIA
PaCa-2 cells, HGF stimulated invasion of pancreatic cancer cells.
HGF (10 ng ml–1) potently stimulated the invasion of KP-1N, KP-
2, KP-3 and SUIT-2 cells by 2.1-fold, 3.4-fold, 4.4-fold, and 
4.7-fold (Figure 4A), respectively. In cases of AsPC-1 and H-48N
cells, the number of invasive cells was few, but HGF did stimulate
invasion of these cells. Therefore, HGF is a potent stimulator of
invasion in many but not all pancreatic cancer cells. Inhibitory
effects of NK4 on tumour cell invasion were then examined using
SUIT-2, KP-1N and KP-3 cells. In the absence of HGF, the number
of invading cells was fewer than 20 field–1 (Figure 4B). The addi-
tion of 110 pM HGF strongly stimulated the invasion of SUIT-2
cells through the Matrigel membrane, whereas NK4 dose-depen-
dently blocked the invasion induced by HGF. The invasion stimu-
lated by 110 pM HGF was significantly inhibited by 1.1 nM NK4
and was almost completely inhibited by 110 nM NK4, a 1000-fold
higher concentration of HGF. The addition of 110 nM NK4 alone
had no apparent effect on invasion of the cells. Similarly, 110 nM
NK4 inhibited invasion of KP-1N and KP-3 cells enhanced by 110
pM HGF, while NK4 alone had no effect on invasion of these cells
(Figure 4C). 
Since invasive behaviour of carcinoma cells is regulated by
interactions with stromal fibroblasts, we asked if the invasive
potential of SUIT-2 pancreatic cancer cells is regulated by interac-
tion with pancreatic fibroblasts. SUIT-2 cells were cultured on the
Matrigel, while fibroblasts were cultured in the outer well. When
SUIT-2 cells were cultured alone without fibroblasts, the number
of SUIT-2 cells which invaded through Matrigel and the
membrane was below 10 cells per field, as shown in Figure 5. In
contrast, SUIT-2 cells markedly invaded when they were cultured
with fibroblasts: the number of invaded cells increased by 6.6-
fold by cocultivation with fibroblasts. Importantly, NK4 dose-
dependently blocked the invasion of SUIT-2 cells in the presence
of cocultured fibroblasts. Complete inhibition by NK4 was seen
with 110 nM. The addition of antibody against HGF also inhibited
the invasion stimulated by fibroblasts (Figure 5). These results
indicate that: 1. the invasive potential of SUIT-2 cells is strongly
enhanced by interaction with stromal fibroblasts; 2. the fibroblast-
derived factor which enhances SUIT-2 invasion is HGF; and 3.
NK4 abrogates SUIT-2–fibroblasts interaction as mediated by
HGF, and thereby inhibits SUIT-2 invasion. 
NK4 inhibits cancer invasion stimulated by ascitic fluid
after resection 
Since surgical resection of carcinomas often results in acceleration
of cancer progression and dissemination (Kodama et al, 1992;
Bogden et al, 1997), we considered that HGF might influence the
invasive potential of pancreatic cancers after surgery. To address
this issue, SUIT-2 cells were cultured in the Matrigel invasion
chamber in the presence of ascites obtained from a surgical patient
with pancreatic cancer (Figure 6A). As demonstrated above, inva-
sion of SUIT-2 cells was strongly stimulated by the addition of 110
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pM HGF. Likewise, the addition of ascitic fluid strongly stimu-
lated the invasion of SUIT-2 cells and the maximal activity of
ascites to stimulate cancer invasion was much higher than that of
110 pM HGF. The potent stimulatory effect on SUIT-2 cell inva-
sion was also evident in ascites obtained from other patients (not
shown). Therefore, the ascitic fluid obtained after surgery of
pancreatic cancer contains a factor(s) which stimulates the inva-
sion of SUIT-2 cells. 
To determine if HGF is involved in the potent ability of ascitic
fluid to stimulate tumour invasion, HGF levels in ascites were
determined using ELISA. The HGF level in sera of healthy volun-
teers was 0.36 ± 0.13 ng ml–1 (Uchiyama et al, 1999), while levels
in ascitic fluid obtained after pancreatic cancer surgery were 
much higher. The mean ascitic HGF level obtained 2 days after
surgery reached 7.0 ng ml–1 (Figure 6B), then the level gradually
decreased. 
Whether or not NK4 inhibits tumour invasion stimulated 
by ascites obtained after pancreatic cancer surgery was also 
determined. The addition of the ascites strongly stimulated the
invasion of SUIT-2 cells, whereas the invasion stimulated by the
ascites was dose-dependently inhibited by NK4 and the highest
concentration of NK4 (110 nM) almost completely inhibited inva-
sion of SUIT-2 cells (Figure 6C). We propose that HGF in ascitic
fluid is responsible for the potent activity required to stimulate
invasion. 
DISCUSSION 
The identification of potential targets for therapeutic intervention
in the cancer patient will be aided by a better understanding of
molecular and cellular mechanisms which underlie tumour in-
vasion and metastasis. Previous studies and our present study
indicate that the c-Met/HGF receptor is expressed in not all but in
many distinct types of human pancreatic cancer cell lines and
pancreatic cancer tissues, and that HGF affects growth, locomo-
tion and invasive behaviour of pancreatic cancer cells (Ebert et al,
1994; Di Renzo et al, 1995; Furukawa et al, 1995; Paciucci et al,
1998). Our results particularly strengthen the notion of involve-
ment of HGF in invasive potential rather than growth potential in
human pancreatic cancers. Since previous (Paciucci et al, 1998)
and our present results showed that production of HGF in pancre-
atic cancer cell lines is either undetectable or is low and that HGF
mediated fibroblast-dependent invasion of pancreatic cancer cells,
HGF is likely to be a stromal mediator which affects invasion and
probably subsequent metastasis and dissemination of pancreatic
cancer cells. Taken together with the notion that HGF is a potent
inducer of angiogenesis (Bussolino et al, 1992; Van Belle et al,
1998; Morishita et al, 1999), the abrogation of functional associa-
tion between HGF and the Met/HGF receptor would be consider-
able to suppress malignant behaviour of human pancreatic cancer
cells. 
Although molecular mechanisms by which HGF exhibits
profound effects on tumour cell invasion have not been fully
defined, it is known that HGF activates intracellular and extracel-
lular events that lead to dissociation and invasion of cancer cells.
HGF decreases cadherin-mediated adhesiveness (Watabe et al,
1993; Shibamoto et al, 1994; Tannapfel et al, 1994; Nabeshima 
et al, 1998), enhances cell-matrix interaction through the recruit-
ment of integrins, p125FAK, and paxillin into focal adhesion
complexes and concomitant protein phosphorylation of p125FAK
0
0 110 0 1.1 11 110
10
20
30
40
50
N
u
m
b
e
r
 
o
f
 
i
n
v
a
s
i
v
e
 
c
e
l
l
s
/
f
i
e
l
d
HGF (110 pM)
NK4
(nM)
SUIT-2
+ - + - + - + - + - + - + - + -
40
30
20
10
0
N
u
m
b
e
r
 
o
f
 
i
n
v
a
s
i
v
e
 
c
e
l
l
s
/
f
i
e
l
d
A
B
AsPC-1
BxPC-3
H-48N
KP-1N
KP-2
KP-3
PaCa-2
SUIT-2
HGF
(10 ng/ml)
Figure 4 Stimulatory effect of HGF on (A) invasion of human pancreatic
cancer cells, (B) inhibition of SUIT-2, (C) KP-1N and KP-3 pancreatic cancer
cell invasion by NK4. Pancreatic cancer cells were seeded on Matrigel and
cultured for 24 h in the absence or presence of HGF and/or NK4. 40 mg and
20 mg of Matrigel respectively were coated on Transwell membrane in (A)
and (B, C). The number of invasive cells that invaded through Matrigel and
the filter membrane to the underside of the membrane was counted. Each
value represents the mean ± SD of triplicate measurements 
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and paxillin (Matsumoto et al, 1994; Jiang et al, 1996). HGF stim-
ulates proteolytic breakdown of the extracellular matrix, through
enhancing matrix methaloproteinases (MMPs) and urokinase-type
plasminogen activator (uPA)-dependent proteolytic network
(Pepper et al, 1992; Jeffers et al, 1996; Date et al, 1998; Kadono et
al, 1998; Rosenthal et al, 1998). On the other hand, we found that
NK4 inhibits scattering, migration and invasion of SUIT-2 cells,
induced by HGF, cocultured fibroblasts and ascitic fluid obtained
from patients who underwent pancreatic cancer surgery. NK4
binds to the c-Met/ HGF receptor with a 10-fold lower affinity than
HGF, while tyrosine phosphorylation of the c-Met/HGF 
receptor was almost completely inhibited by NK4 at 1000-fold
higher concentration than that of HGF (Date et al, 1997, 1998;
Kuba et al, 2000). NK4 dose-dependently inhibited pancreatic
cancer cell migration and invasion, which coincides with the
competitive inhibition of HGF-binding to the Met receptor by
NK4. NK4 inhibits MMP-9 and uPA activities stimulated by HGF
and NK4 inhibits migration and invasion of distinct types of
cancer cells, including gallbladder, colon and breast cancer cells
(Date et al, 1998; Hiscox et al, 2000; Parr et al, 2000). It is likely
that NK4 inhibits HGF-dependent intracellular and extracellular
events that accelerate the dissociation and invasion in pancreatic
cancer cells. 
Acceleration of cancer progression after surgery is evident in
clinical settings and in experimental animals (Kodama et al, 1992;
Bogden et al, 1997). This means that tissue injury accompanying
surgical treatment may offer the specific environment which influ-
ences dissemination of cancer cells, if residual cancer cells are
present in the resected margin or in the wound fluid. In pancreatic
cancer treatment, disseminative cancer spreading and metastasis
often follows surgical removal of the primary tumour (Sperti et al,
1997). We found that high levels of HGF exist in peritoneal fluid
after pancreatic cancer surgery and that incubation with ascitic
fluid strongly stimulates invasion of pancreatic cancer cells, yet
this invasion was almost completely inhibited by an HGF-antago-
nist and neutralizing HGF antibody. This finding suggests that
HGF may be involved in the aggressive invasion, dissemination,
and/or metastasis of postoperative pancreatic cancer. Previous
studies also noted that HGF is present in most pleural and peri-
toneal fluid after lung and hepatic surgery respectively (Eagles et
al, 1996; Kimura et al, 1996; Uchiyama et al, 1999). Although
tissue and serum HGF levels rapidly increase after tissue injuries
and HGF plays an important role in tissue regeneration (Zarnegar
and Michalopoulos, 1995; Matsumoto and Nakamura, 1997), in
cancer tissues, HGF in the wound fluid may accelerate spreading
and dissemination of remnant cancer cells. Inhibition
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Figure 5 Inhibitory effect of NK4 on invasion of SUIT-2 pancreatic cancer cells in coculture with fibroblasts. (A) Appearance of invaded SUIT-2 cells. SUIT-2
cells were cultured for 24 h without fibroblasts (a), or were cocultured with fibroblasts in the absence (b) or presence of 110 nM NK4 (c). 20 mg of Matrigel was
coated on the Transwell membrane. (B) The number of cells that invaded through Matrigel and the filter membrane. SUIT-2 cells were cultured for 24 h without
fibroblasts, or they were cocultured with fibroblasts in the absence or presence of 11 nM or 110 nM NK4. Each value represents the mean ± SD of triplicate
measurements of ascites-induced invasion of pancreatic cancer cells by NK4
suggests the possibility that NK4 may be applicable to treat
pancreatic cancer patients who have had surgery. 
In conclusion, HGF potently stimulates dissociation and the
invasive potential of pancreatic cancer cells and is likely to be
involved in invasion, dissemination and metastasis of pancreatic
cancers, possibly through tumour–stromal interaction and also
after pancreatic cancer surgery. NK4, an effective antagonist of
HGF-induced invasive and metastatic behaviour, may have the
potential for anti-invasion/metastatic therapy. 
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